Tamoxifen Tablets British Dragon

Subtotal	$0.00
Shipping	$0.00
Total	$0.00

Active Substance: Tamoxifen Citrate
Brand Name: Nolvadex
Compound Class: SERM — Selective Estrogen Receptor Modulator (not an anabolic steroid)
Manufacturer: British Dragon
Concentration: 20 mg per tablet
Pack Size: 100 tablets
Half-Life: ~5–7 days (active metabolites; longest half-life of any common SERM)
Onset to Steady State: ~2 weeks of consistent daily dosing
Primary Use: Post-cycle therapy (PCT), on-cycle gynecomastia management, breast tissue estrogen receptor blockade
PCT Mechanism: Hypothalamic/pituitary ER antagonism → blocks estrogen feedback → increases GnRH → stimulates LH and FSH → restores endogenous testosterone production
Anti-Gyno Mechanism: Direct estrogen receptor antagonism in breast tissue — blocks estrogenic stimulation of mammary gland development
Hepatotoxicity: None at standard doses
Note for HGH users: Tamoxifen suppresses circulating IGF-1 — concurrent use with Somatrobol (HGH) should account for this interaction

$45.00

In Stock

Manufacturer	British Dragon
Brand	Nolvadex
Substance	Tamoxifen Citrate
Concentration	20 mg/tab
Pack Size	100 tabs

Shipping

International U.S. Domestic

Description
FAQ

Tamoxifen Citrate: The SERM With Breast Tissue Selectivity

Tamoxifen Citrate (Nolvadex) is the SERM most closely associated with gynecomastia management in performance pharmacology — and for sound pharmacological reasons. Where Clomiphene Citrate's primary clinical strength lies in potent LH and FSH stimulation from the hypothalamic-pituitary level, Tamoxifen's defining characteristic is its tissue-selective estrogen receptor antagonism, expressed most strongly in breast tissue. In breast glandular cells, Tamoxifen acts as a pure estrogen receptor antagonist — blocking estrogenic stimulation of breast tissue regardless of circulating estradiol levels.

This selectivity was characterised in clinical breast cancer research long before performance athletes began using the compound. The same mechanism that makes Tamoxifen the cornerstone of hormone-receptor-positive breast cancer treatment makes it the most effective non-surgical intervention for anabolic steroid-induced gynecomastia in the performance setting. No other compound in this catalog provides this degree of breast tissue estrogen receptor blockade in a single oral tablet.

How Tamoxifen Restores Natural Testosterone — The HPT Axis Mechanism

At the hypothalamic and pituitary level, Tamoxifen acts as a partial estrogen receptor agonist/antagonist — blocking estrogen's negative feedback on GnRH and gonadotropin release in the same way Clomiphene does. Anabolic steroid use suppresses LH and FSH production through two pathways: direct androgenic suppression and the secondary increase in estradiol from aromatization, which further suppresses the hypothalamic-pituitary axis. Tamoxifen addresses the estrogenic suppression component directly, while the androgenic suppression clears progressively as the cycle ends and exogenous compounds clear.

Tamoxifen occupies estrogen receptors in the hypothalamus and pituitary, preventing estradiol from signalling suppression of GnRH release
The hypothalamus responds by increasing GnRH pulse frequency and amplitude
GnRH stimulates the pituitary to release LH and FSH
LH signals Leydig cells in the testes to resume testosterone synthesis; FSH signals Sertoli cells to resume spermatogenesis
Natural testosterone production recovers progressively over the PCT period

Tamoxifen's uniquely long active half-life — 5–7 days for its primary metabolites Endoxifen and 4-hydroxytamoxifen — means it requires approximately 2 weeks of daily dosing to reach full steady-state plasma concentrations. This is a pharmacokinetic characteristic no other common SERM shares. In practical PCT terms: the full HPT axis stimulation effect of Tamoxifen builds across the first two weeks of use, rather than producing its maximum LH/FSH drive from day one of use.

Tamoxifen vs Clomiphene — Complementary Rather Than Interchangeable

Both Tamoxifen and Clomiphene are SERMs; both stimulate the hypothalamic-pituitary axis to increase LH and FSH. They are not duplicates. Their differences in tissue selectivity, receptor binding profile, and side effect character make them complementary in combined PCT protocols rather than interchangeable alternatives:

Breast tissue antagonism: Tamoxifen is superior. Its affinity for breast tissue estrogen receptors is significantly higher than Clomiphene's. For gynecomastia management — whether prevention during a cycle or treatment of existing glandular tissue — Tamoxifen is the appropriate compound.
LH/FSH stimulation potency: Clomiphene produces a more pronounced acute LH and FSH response per dose. This makes Clomiphene the dominant driver in combined PCT protocols, with Tamoxifen providing the breast tissue protection and supplementary axis stimulation.
Side effect profile: Clomiphene more commonly produces mood disturbances, visual symptoms (phosphenes, floaters), and emotional instability at standard PCT doses. Tamoxifen's CNS side effect burden is generally milder — hot flashes and mild mood effects are the most common reports. Athletes who find Clomiphene difficult to tolerate psychologically frequently run Tamoxifen solo PCT.
Estrogenic activity at non-target tissues: Both compounds have tissue-selective partial agonist activity. Tamoxifen acts as a partial estrogen agonist in bone (beneficial for bone mineral density) and liver, but as an antagonist in breast tissue. These tissue-selective effects are distinct from Clomiphene's profile and contribute to the clinical rationale for running both compounds in combination.
Combined protocol synergy: Tamoxifen + Clomiphene run simultaneously produce superior testosterone recovery compared to either compound alone in most contexts. Clomiphene drives the LH/FSH stimulation; Tamoxifen maintains breast tissue estrogen receptor blockade and reinforces hypothalamic axis signalling through its independent receptor binding. This is the gold-standard PCT structure.

Dosing Protocol for Tamoxifen 20 mg Tablets

PCT loading dose: 40 mg/day (2 tablets) for the first 2 weeks of PCT. The loading dose compensates for Tamoxifen's 2-week steady-state lag, providing higher plasma concentrations during the critical early PCT window when endogenous testosterone production is most suppressed.
PCT maintenance dose: 20 mg/day (1 tablet) for weeks 3–4 (or weeks 3–6 for longer or more suppressive cycles). By week 3, the compound is at steady state and the lower maintenance dose sustains effective HPT axis stimulation.
Standard 4-week solo PCT: Weeks 1–2 at 40 mg/day; weeks 3–4 at 20 mg/day. Appropriate for moderately suppressive cycles with single-compound or low-dose multi-compound structures.
Extended PCT for highly suppressive cycles: 40 mg/day for weeks 1–2; 20 mg/day for weeks 3–6. Indicated after long cycles with highly suppressive compounds — Nandrolone, Trenbolone, or extended high-dose testosterone.
On-cycle gynecomastia management dose: 20–40 mg/day until the gynecomastia resolves or stabilises. Note: Tamoxifen manages existing gynecomastia by blocking further estrogenic stimulation, but cannot reverse established glandular proliferation — it addresses the cause, not the accumulated tissue. For prevention, aromatase inhibitors are more effective; Tamoxifen is the response tool when gynecomastia has already emerged.
Pack supply: 100 tablets at 20 mg. A standard 4-week PCT (2 weeks × 2 tablets/day + 2 weeks × 1 tablet/day = 28 + 14 = 42 tablets) covers 2.3 complete cycles per pack. A 6-week extended PCT uses approximately 56 tablets, providing 1.8 cycles per pack.

Most Effective PCT Applications

Tamoxifen solo PCT (40/40/20/20 mg/day) after moderate-suppression cycles — for athletes completing single-compound or low-dose anabolic cycles where the primary need is reliable HPT axis restart without the CNS side effects that Clomiphene produces in a subset of users. Oral-only cycles (Methanabol, Oxanabol, Stanabol Tablets), single-ester testosterone cycles at standard performance doses, and short-duration injectable cycles all respond well to solo Tamoxifen PCT without requiring Clomiphene's additional HPT axis stimulation.
Tamoxifen (20–40 mg/day) + Clomiphene Tablets combined PCT for high-suppression cycles — the protocols following Nandrolone (Decabol 250, Durabol 100), Trenbolone (Trenabol), or long multi-compound cycles require maximum HPT axis stimulation alongside persistent breast tissue protection. Combined PCT runs both SERMs simultaneously: Clomiphene at 50–100 mg/day (weeks 1–2) tapering to 25–50 mg/day (weeks 3–4) alongside Tamoxifen at 40 mg/day (weeks 1–2) tapering to 20 mg/day (weeks 3–4).
Tamoxifen on-cycle (20–40 mg/day) for active gynecomastia management — when gynecomastia develops during a cycle despite AI use — or when AI use was insufficient, delayed, or not implemented — Tamoxifen provides the most direct intervention. An aromatase inhibitor prevents estrogen from being produced; Tamoxifen blocks existing estrogen from acting at the breast tissue receptor. In an active gynecomastia situation (nipple sensitivity, early glandular tissue formation), running both simultaneously addresses both the estrogenic drive (AI) and the tissue receptor activation (Tamoxifen).

Side Effects and the IGF-1 Consideration for HGH Users

Hot flashes — the most commonly reported side effect of Tamoxifen use, across both clinical and performance populations. Caused by the compound's estrogenic antagonism in the hypothalamus affecting thermoregulation. Typically mild and transient, resolving spontaneously within 1–2 weeks of consistent dosing as the body adapts.
Mood effects — generally milder than Clomiphene's documented mood and cognitive effects. Some athletes report mild emotional flatness or reduced motivation during Tamoxifen PCT; this is typically less pronounced than the mood disruption associated with Clomiphene. Athletes highly sensitive to estrogenic fluctuation may find the transient estrogen suppression during PCT produces these effects regardless of which SERM is used.
Venous thromboembolism risk — Tamoxifen's most clinically serious potential effect. The same estrogen receptor activity in the liver that produces beneficial lipid changes also increases clotting factor production. Deep vein thrombosis and pulmonary embolism risk is elevated with long-term Tamoxifen use in clinical populations. At the short duration of standard PCT (4–6 weeks), this risk is minimal for healthy athletes with no pre-existing clotting disorders or history of thromboembolism.
IGF-1 suppression — critical for Somatrobol users: Tamoxifen reduces circulating IGF-1 levels through estrogen receptor modulation in the liver. IGF-1 is the primary mediator of human growth hormone's anabolic and lipolytic effects. Athletes running Somatrobol (HGH) concurrently with Tamoxifen should be aware that the IGF-1 reduction from Tamoxifen measurably blunts the tissue anabolic output of the HGH cycle. If HGH is a central component of the protocol, Toremifene or Raloxifene are preferable SERMs for PCT, as neither suppresses IGF-1 to the same extent.
Lipid profile effects — unlike aromatase inhibitors, which often negatively impact HDL cholesterol by suppressing total estrogen activity, Tamoxifen tends to produce neutral or mildly positive lipid effects. It acts as a partial estrogen agonist in the liver, preserving some of estrogen's beneficial lipid effects while blocking breast tissue receptors. This is a clinical advantage over AI-based estrogen management during PCT from a cardiovascular lipid perspective.

Conclusion

Tamoxifen Tablets by British Dragon are the definitive SERM for breast tissue estrogen receptor blockade in anabolic steroid pharmacology. As a PCT compound, Tamoxifen's unique combination of breast tissue selectivity, manageable side effect profile, and persistent HPT axis stimulation makes it the preferred single SERM choice for athletes who prioritise gynecomastia protection alongside testosterone recovery. In combination with Clomiphene, it forms the gold-standard PCT protocol for the most suppressive cycles in this catalog.

Its long active half-life — requiring 2 weeks to reach full steady state — distinguishes its pharmacokinetic behaviour from every other SERM and informs its loading dose protocol. And its one critical interaction — IGF-1 suppression in the presence of HGH — defines the single clinical context where it is not the automatic default choice. Within every other PCT structure and gynecomastia management scenario this catalog produces, Tamoxifen is the estrogen management backbone of PCT in this catalog.

When should Tamoxifen be started after the last injection, and does the ester matter?

Tamoxifen PCT timing is determined by the slowest-clearing compound in the cycle — not by Tamoxifen's own pharmacokinetics. Beginning PCT while significant exogenous androgens remain active suppresses the HPT axis response to SERM stimulation and negates the PCT's purpose. Practical timing guidelines: after Testosterone Propionate or short-ester compounds, begin Tamoxifen 3–4 days after the last injection. After Testosterone Enanthate or Cypionate, wait 14–18 days. After Sustabol 350 (which contains Testosterone Decanoate), wait approximately 21 days. After Decabol 250 (Nandrolone Decanoate), wait 21–28 days. Oral-only cycles: begin Tamoxifen 2–3 days after the last tablet. The 2-week loading period of Tamoxifen means its full HPT axis effect builds during the critical first two weeks of PCT — starting at the correct timing ensures that plateau is reached during the period of active recovery rather than after it.

Is Tamoxifen better than an aromatase inhibitor for gynecomastia prevention during a cycle?

For prevention of gynecomastia in an aromatizing cycle, aromatase inhibitors (Anastrozole, Exemestane, Letrozole) are superior to Tamoxifen. AIs reduce the total amount of estrogen available in the system — they address the root cause. Tamoxifen blocks estrogen receptors in breast tissue but does not lower circulating estradiol, meaning elevated estrogen continues to act on other tissues and the management is symptomatic rather than systemic. The practical consequence: athletes who use Tamoxifen as the sole on-cycle estrogen control may still experience water retention, blood pressure elevation, and mood effects from circulating estradiol even if breast tissue is protected. AIs are the correct primary on-cycle estrogen management tool. Tamoxifen is the correct breast tissue rescue tool when gynecomastia develops despite AI use, or when an AI is not available or tolerated.

Why does Tamoxifen take 2 weeks to reach full effect, and how should PCT be structured around this?

Tamoxifen's primary active metabolites — 4-hydroxytamoxifen and Endoxifen — have half-lives of approximately 7 and 14 days respectively. With half-lives this long, it takes 5–7 half-lives of consistent daily dosing before the compound reaches steady-state plasma concentrations where its HPT axis effect is fully expressed. At 5 half-lives of the 7-day metabolite, that is approximately 35 days — but meaningful activity builds progressively from day one. The practical implication is that Tamoxifen's LH/FSH stimulation is increasing throughout weeks 1–4 of PCT, peaking at steady state after approximately 2 weeks of daily dosing. The 40 mg/day loading dose in weeks 1–2 is specifically designed to accelerate the approach to therapeutically effective plasma levels, providing higher initial concentrations during the early PCT window when testosterone suppression is deepest. Reducing to 20 mg/day at week 3 maintains the steady state established by the loading phase.

Can Tamoxifen treat existing gynecomastia developed during a cycle, or can it only prevent further development?

Tamoxifen can arrest and partially reverse early-stage gynecomastia if introduced promptly when symptoms appear. At 40 mg/day, consistent Tamoxifen use over 4–8 weeks after early gynecomastia signs (nipple sensitivity, tenderness, minor puffiness) can reduce the glandular tissue that has begun developing by blocking continued estrogenic stimulation. Studies in adolescent pubertal gynecomastia — a mechanistically similar condition — have demonstrated partial regression with Tamoxifen treatment in early stages. However, once glandular proliferation has progressed to established fibrous breast tissue — typically after several months of unmanaged gynecomastia — Tamoxifen can stop further development but cannot reverse the accumulated tissue. Mature gynecomastia is addressed only by surgical excision. The clinical lesson is that early response is critical: Tamoxifen's efficacy for gynecomastia reversal is inversely proportional to how long the glandular development has been allowed to progress.

Why does Tamoxifen lower IGF-1, and when does this matter in practice?

Tamoxifen modulates estrogen receptor activity in the liver, where estrogen receptors normally regulate growth hormone receptor expression and IGF-1 synthesis. By blocking hepatic estrogen receptor activation, Tamoxifen reduces the liver's production of IGF-1 in response to growth hormone signalling. In a standard PCT following an anabolic steroid cycle without HGH, this IGF-1 reduction has minimal practical impact — the athlete is not relying on circulating IGF-1 as a primary anabolic driver during PCT. The interaction becomes clinically relevant specifically when HGH (Somatrobol) is running concurrently with Tamoxifen. HGH's primary tissue-building and lipolytic effects are mediated through IGF-1; reducing IGF-1 directly reduces the return on the HGH investment. Athletes who run long HGH cycles that span the PCT window should consider Clomiphene-only PCT during the HGH phase, and can introduce Tamoxifen only after the HGH cycle concludes if breast tissue management remains a priority.

Tamoxifen Tablets